ABT-866

• Description:

  ABT-866 is an α1A-adrenoceptor agonist and an antagonist at the α1B- and α1D-adrenoceptor subtypes. ABT-866 has an EC50 of 0.60 μM for the α1A in the rabbit urethra. ABT-866 has a pA2 value of 5.4 for the α1B in the rat spleen. ABT-866 has a pA2 value of 6.2 for the α1D in the rat aorta. ABT-866 exhibits good urethral selectivity and lower cardiovascular side effects in stress urinary incontinence models. ABT-866 can be used for the research of diseases such as stress urinary incontinence[1][2].

• UNSPSC:

  12352005

• Hazard Statement:

  H302-H315-H319-H335

• Target:

  Adrenergic Receptor

• Related Pathways:

  GPCR/G Protein; Neuronal Signaling

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Endocrinology; Cardiovascular Disease

• Smiles:

  O=S(NC1=CC=CC(CC2=CN=CN2)=C1)(CC)=O

• Molecular Formula:

  C12H15N3O2S

• Molecular Weight:

  265.33

• Precautions:

  P261-P280-P302+P352

• References & Citations:

  [1]Buckner SA, et al. ABT-866, a novel alpha (1A) -adrenoceptor agonist with antagonist properties at the alpha (1B) - and alpha (1D) -adrenoceptor subtypes. Eur J Pharmacol. 2002 Aug 2;449 (1-2) :159-65.|[2]Altenbach RJ, et al. N-[3- (1H-imidazol-4-ylmethyl) phenyl]ethanesulfonamide (ABT-866, 1), (1) a novel alpha (1) -adrenoceptor ligand with an enhanced in vitro and in vivo profile relative to phenylpropanolamine and midodrine. J Med Chem. 2002 Sep 26;45 (20) :4395-7.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 1

• CAS Number:

  [258526-74-8]